CoChat

Fatal Hepatotoxicity Associated with Troglitazone

Vella, Adrian, de Groen, Piet C., Dinneen, Sean F. · 1998 · Annals of Internal Medicine
Cited by 76

The DOI matches its Crossref record.

Abstract

Letters15 December 1998Fatal Hepatotoxicity Associated with TroglitazoneAdrian Vella, MD, Piet C. de Groen, MD, and Sean F. Dinneen, MD, MScAdrian Vella, MDMayo Clinic and Foundation; Rochester, MN 55905, Piet C. de Groen, MDMayo Clinic and Foundation; Rochester, MN 55905, and Sean F. Dinneen, MD, MScMayo Clinic and Foundation; Rochester, MN 55905Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-12-199812150-00032 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest Dr. Whitcomb's letter concerning, among other issues, hepatotoxicity associated with troglitazone [1]. According to experience in clinical trials to date, troglitazone-related hepatotoxicity is usually asymptomatic, mild, and reversible. However, clinical trial experience of drug toxicity often underestimates the prevalence and severity of adverse events observed during postmarketing use [2]. News of six deaths and one liver transplantation associated with troglitazone led to withdrawal of the product from the British market [3]. We describe another case of fatal hepatitis associated with troglitazone.An 85-year-old man with type 2 diabetes presented with severe hepatic dysfunction. ...References1. Whitcomb RW. Update in endocrinology [Letter]. Ann Intern Med. 1998; 128:871. Google Scholar2. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freed-holm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996; 335:1016-21. Google Scholar3. Troglitazone suspended in UK after more adverse events. SCRIP. 1997; 2290:15. Google Scholar4. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med. 1998; 338:861-6. Google Scholar5. Physicians' Desk Reference. Montvale, NJ: Medical Economics Pr; 1998:2118-21. Google Scholar Author, Article, and Disclosure InformationAffiliations: Mayo Clinic and Foundation; Rochester, MN 55905 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByIntegrating in vitro testing and physiologically-based pharmacokinetic (PBPK) modelling for chemical liver toxicity assessment—A case study of troglitazoneWhat Is Pharmacoepidemiology?Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and futureHow to Avoid Being Surprised by Hepatotoxicity at the Final Stages of Drug Development and ApprovalDesign, Synthesis, Biological Activity and Molecular Dynamics Studies of Specific Protein Tyrosine Phosphatase 1B Inhibitors over SHP-2Hepatotoxicity of Cardiovascular and Antidiabetic DrugsWhat is Pharmacoepidemiology?The safety of thiazolidinedionesRole of Peroxisome Proliferator-Activated Receptor-.GAMMA. in Atherosclerosis - An Update -Improving the Reporting of Adverse Drug Reactions in the Hospital SettingImportant Elements for the Diagnosis of Drug-Induced Liver InjuryThe Role of Drug Metabolism in ToxicityDIABETES MELLITUSCurrent and novel therapies for the treatment of nonalcoholic steatohepatitisGene Expression Analysis of Troglitazone Reveals Its Impact on Multiple Pathways in Cell Culture: A Case for In Vitro Platforms Combined with Gene Expression Analysis for Early (Idiosyncratic) Toxicity ScreeningINVESTIGATION OF PROTEOMIC BIOMARKERS IN IN VIVO HEPATOTOXICITY STUDY OF RAT LIVER: TOXICITY DIFFERENTIATION IN HEPATOTOXICANTSCombination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitusTroglitazone and liver injury: In search of answersAcarbose treatment in liver disease: Cognitive or glycemic control?Thiazolidinediones and InsulinHepatotoxicity of thiazolidinedionesHepatotoxicity of the thiazolidinedionesTroglitazone-induced liver failure: a case studyTroglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitusTroglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in ratsEvaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction"Did This Drug Cause My Patient's Hepatitis?" and Related QuestionsDavid W. Nierenberg, MDDifferentiating members of the thiazolidinedione class: a focus on safetyTratamiento de la diabetes mellitus: objetivos generales y manejo en la práctica clínicaHepatotoxicity of thiazolidinedionesMicroscopic Analysis of Oxidative Stress in Cultured Cells. II. Transmission Electron MicroscopyOral agents for the treatment of type 2 diabetes mellitus: Pharmacology, toxicity, and treatmentFactors Associated with the Risk of Liver Enzyme Elevation in Patients with Type 2 Diabetes Treated with a ThiazolidinedioneTroglitazone-Associated Hepatotoxicity Treated Successfully with SteroidsKathleen A. Prendergast, MD, Carl L. Berg, MD, and Ralph Wisniewski, MDRECENT ADVANCES IN THE PHARMACOLOGIC MANAGEMENT O

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-129-12-199812150-00032

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 76

Metadata

Authors
Vella, A., de Groen, P. C., & Dinneen, S. F.
Venue
Annals of Internal Medicine
Published
1998-12-15
Volume
129
Issue
12
Pages
1080
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2067677086
Cited by
76
References
0
FWCI
10.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fatal Hepatotoxicity Associated with Troglitazone. https://app.cochat.ai/papers/10.7326/0003-4819-129-12-199812150-00032
The paper
Vella, A., de Groen, P. C., & Dinneen, S. F. (1998). Fatal Hepatotoxicity Associated with Troglitazone. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-129-12-199812150-00032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.